Matches in SemOpenAlex for { <https://semopenalex.org/work/W2277535953> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2277535953 endingPage "LBA6500" @default.
- W2277535953 startingPage "LBA6500" @default.
- W2277535953 abstract "LBA6500 Background: Dasatinib is a highly potent BCR-ABL kinase inhibitor. Once daily dasatinib demonstrated high rates of durable complete cytogenetic response (CCyR) with 73% progression-free survival and 87% overall survival at 3 yrs in pts with CML-CP post IM failure. DASISION compares efficacy and safety of dasatinib and IM as initial treatment of CML-CP. Methods: 519 pts with Ph(+) newly diagnosed CML-CP stratified by Hasford risk were randomized to dasatinib 100 mg QD (n = 259) or IM 400 mg QD (n = 260). The primary endpoint was 12-mo rate of confirmed CCyR (cCCyR; CCyR on 2 consecutive analyses; any # of metaphases). Other endpoints were rates of and times to CCyR and major molecular response (MMR). Results: Pts characteristics were well balanced. Minimum follow-up was 12 mos; median treatment duration was 14 mos. 85% of dasatinib and 81% of IM pts remained on study. Median dose intensity was 99 mg/d for dasatinib and 400 mg/d for IM. cCCyR rate was superior for dasatinib vs IM (77% vs 66%, P = 0.0067). 12-mo CCyR and MMR rates ( Table ) were higher for dasatinib vs IM (CCyR: 83% vs 72%; MMR: 46% vs. 28%). MMR was obtained significantly faster with dasatinib (HR 2.0, P < 0.0001) as was CCyR (HR 1.5, P < 0.0001). Rates of transformation to AP/BC were 1.9% for dasatinib and 3.5% for IM. Grade 3/4 anemia (10% vs 7%) and neutropenia (21% vs 20%) were similar across arms; thrombocytopenia was more common for dasatinib (19% vs. 10%). Non-hematologic adverse drug reactions (all grades) in ≥10% of pts (dasatinib vs. IM) were fluid retention (19% vs 42%; including pleural effusion, all grade 1 or 2, 10% vs. 0%), nausea (8% vs. 20%), vomiting (5% vs. 10%), myalgia (6% vs.12%), muscle inflammation (4% vs. 17%) and rash (11% vs. 17%). Conclusions: Dasatinib showed significantly higher and faster rates of CCyR and MMR vs IM. Given the predictive value of 12-mo CCyR and MMR and the favorable tolerability of dasatinib, dasatinib may improve long-term outcomes in pts with newly diagnosed CML-CP. [Table: see text] [Table: see text]" @default.
- W2277535953 created "2016-06-24" @default.
- W2277535953 creator A5011133051 @default.
- W2277535953 creator A5015101485 @default.
- W2277535953 creator A5017268845 @default.
- W2277535953 creator A5023183481 @default.
- W2277535953 creator A5035964802 @default.
- W2277535953 creator A5042791124 @default.
- W2277535953 creator A5044224344 @default.
- W2277535953 creator A5051359342 @default.
- W2277535953 creator A5067460152 @default.
- W2277535953 creator A5084379902 @default.
- W2277535953 date "2010-06-20" @default.
- W2277535953 modified "2023-10-15" @default.
- W2277535953 title "Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study." @default.
- W2277535953 doi "https://doi.org/10.1200/jco.2010.28.18_suppl.lba6500" @default.
- W2277535953 hasPublicationYear "2010" @default.
- W2277535953 type Work @default.
- W2277535953 sameAs 2277535953 @default.
- W2277535953 citedByCount "12" @default.
- W2277535953 countsByYear W22775359532012 @default.
- W2277535953 countsByYear W22775359532013 @default.
- W2277535953 countsByYear W22775359532014 @default.
- W2277535953 countsByYear W22775359532016 @default.
- W2277535953 crossrefType "journal-article" @default.
- W2277535953 hasAuthorship W2277535953A5011133051 @default.
- W2277535953 hasAuthorship W2277535953A5015101485 @default.
- W2277535953 hasAuthorship W2277535953A5017268845 @default.
- W2277535953 hasAuthorship W2277535953A5023183481 @default.
- W2277535953 hasAuthorship W2277535953A5035964802 @default.
- W2277535953 hasAuthorship W2277535953A5042791124 @default.
- W2277535953 hasAuthorship W2277535953A5044224344 @default.
- W2277535953 hasAuthorship W2277535953A5051359342 @default.
- W2277535953 hasAuthorship W2277535953A5067460152 @default.
- W2277535953 hasAuthorship W2277535953A5084379902 @default.
- W2277535953 hasConcept C126322002 @default.
- W2277535953 hasConcept C141071460 @default.
- W2277535953 hasConcept C203092338 @default.
- W2277535953 hasConcept C2776694085 @default.
- W2277535953 hasConcept C2776960273 @default.
- W2277535953 hasConcept C2777063308 @default.
- W2277535953 hasConcept C2777583451 @default.
- W2277535953 hasConcept C2778461978 @default.
- W2277535953 hasConcept C2778729363 @default.
- W2277535953 hasConcept C2779536868 @default.
- W2277535953 hasConcept C3019892230 @default.
- W2277535953 hasConcept C535046627 @default.
- W2277535953 hasConcept C71924100 @default.
- W2277535953 hasConcept C90924648 @default.
- W2277535953 hasConceptScore W2277535953C126322002 @default.
- W2277535953 hasConceptScore W2277535953C141071460 @default.
- W2277535953 hasConceptScore W2277535953C203092338 @default.
- W2277535953 hasConceptScore W2277535953C2776694085 @default.
- W2277535953 hasConceptScore W2277535953C2776960273 @default.
- W2277535953 hasConceptScore W2277535953C2777063308 @default.
- W2277535953 hasConceptScore W2277535953C2777583451 @default.
- W2277535953 hasConceptScore W2277535953C2778461978 @default.
- W2277535953 hasConceptScore W2277535953C2778729363 @default.
- W2277535953 hasConceptScore W2277535953C2779536868 @default.
- W2277535953 hasConceptScore W2277535953C3019892230 @default.
- W2277535953 hasConceptScore W2277535953C535046627 @default.
- W2277535953 hasConceptScore W2277535953C71924100 @default.
- W2277535953 hasConceptScore W2277535953C90924648 @default.
- W2277535953 hasIssue "18_suppl" @default.
- W2277535953 hasLocation W22775359531 @default.
- W2277535953 hasOpenAccess W2277535953 @default.
- W2277535953 hasPrimaryLocation W22775359531 @default.
- W2277535953 hasRelatedWork W1975185750 @default.
- W2277535953 hasRelatedWork W1984313504 @default.
- W2277535953 hasRelatedWork W2029456196 @default.
- W2277535953 hasRelatedWork W2032615307 @default.
- W2277535953 hasRelatedWork W2100500978 @default.
- W2277535953 hasRelatedWork W2483634774 @default.
- W2277535953 hasRelatedWork W2565606062 @default.
- W2277535953 hasRelatedWork W2567894154 @default.
- W2277535953 hasRelatedWork W2582021609 @default.
- W2277535953 hasRelatedWork W2744568429 @default.
- W2277535953 hasVolume "28" @default.
- W2277535953 isParatext "false" @default.
- W2277535953 isRetracted "false" @default.
- W2277535953 magId "2277535953" @default.
- W2277535953 workType "article" @default.